A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01417533|
Recruitment Status : Recruiting
First Posted : August 16, 2011
Last Update Posted : March 21, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
- GNE Myopathy is a disease that causes walking difficulties and increasing muscle weakness. It usually develops in young adults (between 20 and 30 years of age), and affects arm and leg muscles. HIBM is caused by mutations in a gene that may affect how the muscles function. Researchers want to learn more about the causes, symptoms, and effects of HIBM.
- To collect genetic and medical information from people with GNE Myopathy .
- Individuals between 18 and 80 years of age who have GNE Myopathy and do not use a wheelchair. - Participants must be willing to stop any current treatment of HIBM while enrolled in the study.
- Participants will be screened with a medical history, physical exam, and neurological exam.
- At the first visit, participants will have the following tests:
- Questionnaires about the impact of HIBM on daily activities, mood, and quality of life
- 24-hour urine collection
- Blood samples
- Heart function tests
- Muscle strength and endurance tests, including walking
- Imaging study of the muscles
- Participants will return for followup visits at 6, 12, and 18 months. They may be asked to return for a final visit at 24 months. Not all tests will be performed at each visit.
- Treatment will not be provided as part of this protocol.
For more information, visit our website: http://hibmstudy.nhgri.nih.gov/
|Condition or disease|
|GNE Myopathy GNE Related Diseases|
|Study Type :||Observational|
|Estimated Enrollment :||125 participants|
|Official Title:||A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases|
|Actual Study Start Date :||September 14, 2011|
Patients with a diagnosis of GNE myopathy
Patient with a GNE related disease
Subjects that are a carrier family member or a caregiver of a patient on the study are eligibleto participate.
- Natural History [ Time Frame: Ongiong ]To delineate the natural history of GNE myopathy, and to further characterize the phenotype, progression and complications of the disease.
- Endpoints [ Time Frame: Ongoing ]To identify endpoints and biomarkers of the disease. To study factors that contribute to disease heterogeneity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||4 Years to 80 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Age 4-80 years, either gender, inclusive.
- Diagnosis of GNE myopathy or GNE-related diseases based upon the identification of GNE gene mutations. Molecular confirmation of the diagnosis will be obtained for all subjects in the study.
- Subjects that are a carrier family member of a patient on the study are eligible to participate.
- Must be able to provide informed consent.
- Psychiatric illness or other diseases that would interfere with the subject s ability to comply with the requirements of this protocol.
- Hepatic laboratory parameters (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) or renal laboratory parameters (creatinine, blood urea nitrogen [BUN]) greater than 3 times the upper limit of normal.
- Presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, or gastrointestinal disease not related to the primary disease process.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01417533
|Contact: Andrea I Bowling, C.R.N.P.||(301) firstname.lastname@example.org|
|Contact: Francis Rossignol, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY dial 711 firstname.lastname@example.org|
|Principal Investigator:||Francis Rossignol, M.D.||National Human Genome Research Institute (NHGRI)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||National Human Genome Research Institute (NHGRI)|
|Other Study ID Numbers:||
|First Posted:||August 16, 2011 Key Record Dates|
|Last Update Posted:||March 21, 2023|
|Last Verified:||October 18, 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Hereditary Inclusion Body Myopathy
Nervous System Diseases
Muscular Disorders, Atrophic
Genetic Diseases, Inborn